ArticlePractical laboratory medicine2020
Development of novel parameter for monitoring of malignant melanoma progression.
Article in Practical laboratory medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- Article
- Label-free and noninvasive method for assessing the metabolic status in type 2 diabetic rats with myocardium diastolic dysfunction.Biomedical optics express · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIncreasing HIFs in malignant melanoma, the highly aggressive skin tumour, results in the stimulation of invasiveness. Increased HIF-1α fallouts in inhibition of the activity of some mitochondrial enzymes and leads to preference of cytosol energetic metabolism. Increase of aerobic glycolysis is reflected in an increase of free NADH (Warburg effect) and develops the malignant melanoma.Our goal was to find a link between hypoxia, or hypoxia mimicking factors and the stage of malignant melanoma. Furthermore, we focused on the finding of the experimental parameter which could monitor melanoma patients. PATIENTS AND
methodsWe targeted HIF-1α gene expression and VDR rs2107301 gene polymorphism by PCR analysis. We detected the level of NADH in blood plasma by fluorescence spectroscopy (excitation and emission spectra).
resultsAnalysis of the obtained data from patient samples has shown an increase in HIF-1α which correlates with the disease stage. Investigation VDR rs2107301 polymorphism of patient samples does not show any significant changes in single nucleotide polymorphism, and the low vitamin D level in blood is not a result of VDR mutation in mitochondria. NADH levels vary under hypoxic and pseudohypoxic conditions and refer to the cancer stage.
conclusionsThe apparent mismatch between HIF-1α expression and NADH fluorescence has become the basis for the design of an algorithm for monitoring malignant melanoma based on the sensing of NADH fluorescence and the determination of HIF-1α.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.